Mesenchymal Stem Cell-derived (MSC-EVs) may offer a promising cell-free therapeutic strategy for neurodegenerative diseases.
Neurodegenerative diseases, including Alzheimer's and Parkinson's, are characterized by the progressive loss of neurons.
MSC-EVs contain bioactive substances that can cross the blood-brain barrier and may help regulate neuronal survival and inflammation.
The use of MSC-EVs could avoid some limitations associated with traditional stem cell therapies, such as immunogenicity and ethical concerns.
Challenges remain in the clinical application of MSC-EVs, including the need for standardized isolation techniques and long-term safety evaluations.
MSC-EVs are being studied as potential biomarkers for diagnosing and treating neurodegenerative diseases.
Simplified
Neurodegenerative diseases are a group of chronic diseases characterized by a gradual loss of neurons that worsens over time and dysfunction. These diseases are extremely harmful, not only affecting the physical health of the patients, but also having a serious impact on their quality of life. They mainly include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic lateral sclerosis (ALS), etc. Their pathogenesis is complex, and it is difficult for the existing treatments to effectively slow down the progression of the disease. In recent years, (MSCs) have received widespread attention for their anti-inflammatory, immunomodulatory and neuroprotective properties. In this context, MSC-derived (MSC-EVs) have demonstrated unique therapeutic potential as a cell-free therapeutic strategy. MSC-EVs are rich in bioactive substances such as proteins, lipids, mRNAs and miRNAs, which can pass through the blood-brain barrier and be targeted to the diseased area to regulate neuronal survival, synaptic plasticity and neuroinflammatory responses. In addition, compared with stem cell therapy, MSC-EVs have the advantages of low immunogenicity, easy storage and transportation, and avoiding ethical controversies. However, their clinical application still faces challenges: standardized isolation and purification techniques have not been unified, vesicle loading efficiency and targeting need to be further optimized, and long-term safety needs to be systematically evaluated. This review focuses on the role of MSC-EVs in the development of neurological diseases and explores their possible dual roles, both favorable and unfavorable, in the context of neurological diseases. In addition, this review provides a review of current studies on EVs as potential biomarkers for the diagnosis and treatment of neurodegenerative diseases and provides a comprehensive review of the prospects and challenges of MSC-EVs in clinical applications.
Key numbers
p-tau, Aβ
Markers in AD
Identified in blood and cerebrospinal fluid .
DJ-1, α-syn
Markers in PD
Detected in blood and cerebrospinal fluid .
miRNA, mHTT
Markers in HD
Found in blood and cerebrospinal fluid .
Full Text
We can’t show the full text here under this license.
